

Ref: FOI-000250

Date: 30/8/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

| Question 1 - Does your trust employ one or more homecare medicine services provider(s) to deliver and/or administer medicines to patients in their normal residence? If so, what is the name of the provider(s)? | Question 2 Numbers do not include: new patients in the process of being set up + on-hold patients + patients in the process of restarting + on-hold patients incorrectly put on-hold | Question 3 Numbers do not include: new patients in the process of being set up + on-hold patients + patients in the process of restarting + on-hold patients incorrectly put on-hold | Question 4. For each provider, please provide a list of medications delivered and/or administered through this service. |
|--|--|--|---|
| ALCURA | 23 | 23 | Fremanezumab |
| CALEA | 154 | 154 | Adalimumab |

| | | | |
|-----------|-----|-----|---|
| HEALTHNET | 481 | 481 | Benralizumab, Berotralstat, Bimekizumab, Brodalumab, Dimethyl Fumarate, Diroximel Fumarate, Dupilumab, Filgotinib, Fingolimod, subcutaneous Infliximab, Lanadelumab, Mepolizumab, Omalizumab, Romosozumab, Sarilumab, Teriflunomide, Teriparatide, Tildrakizumab, Tocilizumab, Tralokinumab, Upadacitinib, Subcutaneous Vedolizumab |
| LLOYDS | 315 | 315 | Abatacept, Baricitinib, Glatiramer Acetate, Guselkumab, Secukinumab, Teriparatide, Tocilizumab, Ustekinumab, |
| SCIENSUS | 928 | 928 | Adalimumab, Alirocumab, Apremilast, Certolizumab, Etanercept, Evolocumab, Fampridine, Golimumab, Subcutaneous Immunoglobulin, Icatibant, Infliximab, Interferon beta 1A, Interferon Beta 1B, Ixekizumab, Lanreotide Autogel, Peginterferon Beta 1A, Risankizumab, Somatropin, Tofacitinib, |

| Question 5 - For each provider, how many patient safety incidents were reported in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for. Question 5 JULY 2023 - 2022 - 2021 | Question 6 - For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries were late in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for. Question 6 JULY 2023 - 2022 - 2021 | Question 7 - For each provider, As a proportion of all deliveries, what percentage of medicine and ancillaries deliveries failed in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for. Question 7 JULY 2023 - 2022 - 2021 | Question 8 - For each provider, As a proportion of all clinical services, what percentage of clinical services were late in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for. Question 8 JULY 2023 - 2022 - 2023 | Question 9 For each provider, what proportion of the KPIs for homecare services did your service meet in in the most recent reporting period for which you have data, and in the comparable reporting periods in 2022 and 2021 (eg if giving figs for July 2023, please also give figs for July 22 and July 21)? Please state what period the figures are for. |
|--|--|---|---|--|
| 0 0 0 | 0 0 0 | 0 0 0 | 0 0 0 | The question is not clear, can you send clarification |
| 0 0 1 | 6 15 0 | 0 0 0 | 0 0 0 | |
| 0 0 0 | 1 1 16 | 11 7 1 | 1 1 1 | |
| 0 0 1 | 0 1 4 | 4 4 4 | 0 0 0 | |
| | | | | |

| | | | | |
|---------|---------|----------|-------|--|
| 8 18 17 | 1 12 11 | 47 31 13 | 3 8 2 | |
|---------|---------|----------|-------|--|

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust